Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection

doi:10.3748/wjg.v13.i45.6115

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 45

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2745)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

764

HTML

1808

Figures (1-3)

173

Sum=2745

Dec 7, 2007 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. Dec 7, 2007; 13(45): 6115-6118
Published online Dec 7, 2007. doi: 10.3748/wjg.v13.i45.6115

Full Size Figure Download Figure

Figure 1 Base line FDG PET/CT detecting a highly metabolic metastasis in liver (white arrows, A and B), second FDG PET/CT demonstrating the decreased number and metabolism level of liver metastases and one highly metabolic metastasis in the left lobe of liver (white arrows, C and D), third FDG PET/CT displaying no lesion at the same position (E and F).

Citation: Sun L, Ye HY, Zhang YH, Guan YS, Wu H. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. World J Gastroenterol 2007; 13(45): 6115-6118
URL: https://www.wjgnet.com/1007-9327/full/v13/i45/6115.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i45.6115